- Previous Close
0.0640 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0760 - Volume
0 - Avg. Volume
22,656 - Market Cap (intraday)
-- - Beta (5Y Monthly) -0.23
- PE Ratio (TTM)
-0.00 - EPS (TTM)
-0.0020 - Earnings Date Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments. It makes investments in the healthcare and biotechnology sector with a focus on post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine. Within post-genomics, it invests in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. In the stem cell biology sector, the fund focuses on stem cell therapies. Within convergent technologies, it invests in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. In the silicon biology sector, the fund focuses on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox. It invests in companies based in Australia New Zealand. The fund invests in both listed and unlisted companies.
www.btchealth.com.au--
Full Time Employees
June 30
Fiscal Year Ends
--
Sector
--
Industry
Recent News: BTC.XA
View MorePerformance Overview: BTC.XA
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BTC.XA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BTC.XA
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
28,328.19%
Return on Assets (ttm)
-5.86%
Return on Equity (ttm)
56.41%
Revenue (ttm)
15.33k
Net Income Avi to Common (ttm)
4.34M
Diluted EPS (ttm)
-0.0020
Balance Sheet and Cash Flow
Total Cash (mrq)
794.68k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
51.45k